Grimes & Company’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.87M | Buy |
8,232
+192
| +2% | +$196K | 0.21% | 81 |
|
|
2026
Q1 | $7.4M | Buy |
8,040
+1,358
| +20% | +$1.38M | 0.2% | 89 |
|
|
2025
Q4 | $7.18M | Buy |
6,682
+472
| +8% | +$451K | 0.17% | 95 |
|
|
2025
Q3 | $4.74M | Buy |
6,210
+1,551
| +33% | +$1.15M | 0.12% | 118 |
|
|
2025
Q2 | $3.63M | Buy |
4,659
+321
| +7% | +$249K | 0.1% | 124 |
|
|
2025
Q1 | $3.58M | Buy |
4,338
+186
| +4% | +$155K | 0.11% | 114 |
|
|
2024
Q4 | $3.21M | Buy |
4,152
+79
| +2% | +$65.4K | 0.09% | 119 |
|
|
2024
Q3 | $3.61M | Buy |
4,073
+326
| +9% | +$293K | 0.1% | 111 |
|
|
2024
Q2 | $3.39M | Sell |
3,747
-85
| -2% | -$68K | 0.1% | 108 |
|
|
2024
Q1 | $2.98M | Sell |
3,832
-1,047
| -21% | -$745K | 0.09% | 114 |
|
|
2023
Q4 | $2.84M | Buy |
4,879
+952
| +24% | +$556K | 0.09% | 113 |
|
|
2023
Q3 | $2.11M | Buy |
3,927
+20
| +0.5% | +$10.3K | 0.08% | 120 |
|
|
2023
Q2 | $1.83M | Sell |
3,907
-13
| -0.3% | -$5.45K | 0.07% | 125 |
|
|
2023
Q1 | $1.35M | Buy |
3,920
+131
| +3% | +$44.2K | 0.06% | 135 |
|
|
2022
Q4 | $1.39M | Buy |
3,789
+10
| +0.3% | +$3.55K | 0.06% | 137 |
|
|
2022
Q3 | $1.22M | Buy |
3,779
+18
| +0.5% | +$5.7K | 0.06% | 129 |
|
|
2022
Q2 | $1.22M | Sell |
3,761
-45
| -1% | -$13.5K | 0.06% | 133 |
|
|
2022
Q1 | $1.09M | Sell |
3,806
-76
| -2% | -$19.6K | 0.06% | 153 |
|
|
2021
Q4 | $1.07M | Hold |
3,882
| – | – | 0.05% | 157 |
|
|
2021
Q3 | $897K | Buy |
3,882
+54
| +1% | +$13.3K | 0.04% | 162 |
|
|
2021
Q2 | $878K | Buy |
3,828
+14
| +0.4% | +$2.81K | 0.04% | 156 |
|
|
2021
Q1 | $713K | Sell |
3,814
-794
| -17% | -$155K | 0.03% | 166 |
|
|
2020
Q4 | $778K | Hold |
4,608
| – | – | 0.04% | 156 |
|
|
2020
Q3 | $683K | Sell |
4,608
-16
| -0.3% | -$2.48K | 0.04% | 151 |
|
|
2020
Q2 | $759K | Hold |
4,624
| – | – | 0.05% | 140 |
|
|
2020
Q1 | $641K | Buy |
4,624
+253
| +6% | +$34.8K | 0.06% | 139 |
|
|
2019
Q4 | $574K | Buy |
4,371
+29
| +0.7% | +$3.36K | 0.04% | 175 |
|
|
2019
Q3 | $486K | Hold |
4,342
| – | – | 0.03% | 177 |
|
|
2019
Q2 | $481K | Sell |
4,342
-57
| -1% | -$6.71K | 0.04% | 174 |
|
|
2019
Q1 | $571K | Buy |
4,399
+177
| +4% | +$21.5K | 0.04% | 152 |
|
|
2018
Q4 | $489K | Sell |
4,222
-125
| -3% | -$14K | 0.05% | 149 |
|
|
2018
Q3 | $466K | Buy |
4,347
+50
| +1% | +$5K | 0.04% | 164 |
|
|
2018
Q2 | $367K | Buy |
4,297
+800
| +23% | +$65.7K | 0.03% | 179 |
|
|
2018
Q1 | $270K | Buy |
+3,497
| New | +$282K | 0.03% | 193 |
|
Other funds holding LLY
Grimes & Company's LLY Position: Q2 2026 in Review
Grimes & Company increased its Eli Lilly (LLY) stake by 2.4% in Q2 2026, buying an estimated $196K and bringing the position to 8,232 shares worth $9.87M. The position accounts for 0.21% of the portfolio, ranked #81.
Grimes & Company first reported a position in LLY in Q1 2018 and has held it in 34 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Grimes & Company held 8,232 shares of Eli Lilly worth $9.87M as of Q2 2026.
- Grimes & Company bought 192 Eli Lilly shares in Q2 2026, an estimated $196K.
- Eli Lilly made up 0.21% of Grimes & Company's portfolio in Q2 2026, its #81 holding.
- Grimes & Company first reported a position in Eli Lilly in Q1 2018 and has held it in 34 quarters since.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.